Discover
AKBA
Akebia Therapeutics, Inc.
1.21
25 x 1.15
2 x 1.48
bid
ask
+
0.07
6.14%
14 @ 05:33 AM
1.22 +0.01 (0.83%)
| Ytd | -24.84% | |
| 1y | -66.11% |
1.15
day range
1.25
0.82
52 week range
4.08
| Open | 1.15 | Prev Close | 1.14 | Low | 1.15 | High | 1.25 | Mkt Cap | 324.59M |
| Vol | 6.04M | Avg Vol | 4.72M | EPS | -0.08 | P/E | N/A | Forward P/E | -7.15 |
| Beta | 0.73 | Short Ratio | 4.71 | Inst. Own | 27.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.13 | 200-d Avg | 1.63 | 1yr Est | 5.50 |
| Income Statement | |||
| Total Revenue | 53.54M | ||
| Revenues (USD) | 53.54M | ||
| Cost of Revenue | 12.29M | ||
| Gross Profit | 41.25M | ||
| Operating Expenses | 45.24M | ||
| Research and Development Expense | 14.81M | ||
| Selling, General and Administrative Expense | 30.44M | ||
| Operating Income | -3.99M | ||
| Interest Expense | 4.69M | ||
| Income Tax Expense | 126.00K | ||
| Net Income | -9.05M | ||
| Net Income Common Stock | -9.05M | ||
| Net Income Common Stock (USD) | -9.05M | ||
| Consolidated Income | -9.05M | ||
| Earnings per Basic Share | -0.03 | ||
| Earnings per Basic Share (USD) | -0.03 | ||
| Earnings per Diluted Share | -0.03 | ||
| Earning Before Interest & Taxes (EBIT) | -4.24M | ||
| Earning Before Interest & Taxes (USD) | -4.24M | ||
| Weighted Average Shares | 267.05M | ||
| Weighted Average Shares Diluted | 267.05M | ||
| Balance Sheet | |||
| Cash and Equivalents | 162.64M | ||
| Cash and Equivalents (USD) | 162.64M | ||
| Trade and Non-Trade Receivables | 62.54M | ||
| Current Assets | 243.48M | ||
| Property, Plant & Equipment Net | 3.42M | ||
| Total Assets | 362.52M | ||
| Debt Current | 12.50M | ||
| Total Debt | 48.89M | ||
| Current Liabilities | 173.88M | ||
| Debt Non-Current | 36.40M | ||
| Total Liabilities | 335.15M | ||
| Accumulated Retained Earnings (Deficit) | -1.69B | ||
| Accumulated Other Comprehensive Income | 6.00K | ||
| Shareholders Equity | 27.38M | ||
| Shareholders Equity (USD) | 27.38M | ||
| Assets Non-Current | 119.04M | ||
| Total Debt (USD) | 48.89M | ||
| Deferred Revenue | 4.50M | ||
| Goodwill and Intangible Assets | 59.04M | ||
| Inventory | 13.00M | ||
| Liabilities Non-Current | 161.26M | ||
| Trade and Non-Trade Payables | 8.39M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.53M | ||
| Net Cash Flow from Financing | -926.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -22.19M | ||
| Capital Expenditure | -62.00K | ||
| Issuance (Purchase) of Equity Shares | 151.00K | ||
| Issuance (Repayment) of Debt Securities | -585.00K | ||
| Net Cash Flow from Investing | -62.00K | ||
| Net Cash Flow from Operations | -21.21M | ||
| Share Based Compensation | 3.67M | ||